Dechra Pharmaceuticals PLC — Board/Management Information 2019

Apr 3, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9129U

Dechra Pharmaceuticals PLC

03 April 2019

The information contained within this announcement contains inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Wednesday, 3 April 2019

Dechra® Pharmaceuticals PLC

("Dechra" or "the Company")

Directorate Change

Dechra announces that Richard Cotton, the Company's Chief Financial Officer, has informed the Board of his decision to leave the Company immediately for personal reasons. 

The Board has agreed that with immediate effect Richard will resign as Director and relinquish his current responsibilities but remain available to the Group until 28 June 2019.  The Company would like to thank Richard for his contribution during his service and wish him well for the future.

The search process for a replacement has commenced and a further update on this will be made in due course.  In the interim period, Paul Sandland, DVP EU Finance Director, will assume the role of Acting Chief Financial Officer until a permanent successor to Richard is appointed.

Trading across the Group has continued to witness growth and is in line with management expectations as we stated in the Half Year results released last month.

The Company expects to release its next Trading update in July, ahead of its Annual results scheduled for publication in September.

Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer	Office:  +44 (0) 1606 814 730
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd
Fiona Tooley, Director e-mail: fiona@tooleystreet.com	Mobile: +44 (0) 7785 703 523 Office:  +44 (0) 121 309 0099

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Its expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOALFFLISRIFIIA